1,720,985 research outputs found
figure_3-only_online-4.11-revised – Supplemental material for An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
No full textSupplemental material, figure_3-only_online-4.11-revised for An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes by Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll and Xin Yu in Journal of Psychopharmacology</p
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for insomnia, headache, sedation, and psychiatric disorder.
No full text<p>Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for insomnia, headache, sedation, and psychiatric disorder.</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
No full textObjectiveTo compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.MethodsPopulationadult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms.Interventionsadjunctive aripiprazole vs. adjunctive placebo.Outcome measuresadverse events and efficacy of treatment.Studiesrandomized controlled trials.ResultsFive randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo) met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed) -0.05 to 0.04 (95% confidence interval -0.13 to 0.16); I(2) =0% to 68%, P=0.20 to 0.70). However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I(2) =43%, PConclusionAdjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day
GRADE Analysis: quality assessment of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.
No full text*<p><b>Decrease quality of evidence:</b> a) single-blind method; b) randomization by the antipsychotic weight; c). I<sup>2</sup>>50%; <b><sup>$</sup>Increase quality of evidence:</b> d) RR >5 or <0.2; <b>GRADE Working Group grades of evidence: # High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <b>Very low quality:</b> We are very uncertain about the estimate.</p
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Summary of adverse events and discontinuation.
No full text<p>Summary of adverse events and discontinuation.</p
Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for prolactin level normalization.
No full text<p>Adjunctive aripiprazole vs. placebo for antipsychotic-induced hyperprolactinemia: forest plot for prolactin level normalization.</p
- …
